Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kymera Therapeutics (KYMR) Receivables - Net (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Receivables - Net for 4 consecutive years, with $40.0 million as the latest value for Q2 2025.

  • For Q2 2025, Receivables - Net changed N/A year-over-year to $40.0 million; the TTM value through Jun 2025 reached $40.0 million, changed N/A, while the annual FY2023 figure was $15.0 million, N/A changed from the prior year.
  • Receivables - Net hit $40.0 million in Q2 2025 for Kymera Therapeutics, up from $15.0 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $40.0 million in Q2 2025 and bottomed at $900000.0 in Q1 2021.
  • Average Receivables - Net over 3 years is $18.6 million, with a median of $15.0 million recorded in 2023.